过氧化物酶增殖物激活受体δ研究进展  

Advances in the study of peroxisome proliferator-activated receptorsδ

作　　者：于丹[1] 马红[1] 

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,北京市100050

出　　处：《世界华人消化杂志》2007年第23期2521-2525,共5页World Chinese Journal of Digestology

摘　　要：过氧化物酶增殖物激活受体(PPARs)是配体激活转录因子,属于核受体超家族.自1990年PPARs被发现以来,其在物质代谢、组织细胞分化与疾病的相关性等方面的功能作用逐渐得到认识和重视.PPARs有3种亚型,分别为PPARα,PPARδ/β和PPARγ.随着PPARδ特异选择性激动剂的发现,PPARδ的生物学功能及其与各种疾病的关系渐渐成为研究热点.目前已经发现PPARδ主要控制脂肪组织和骨骼肌细胞的脂类代谢和能量平衡,并参与许多疾病的发生和发展过程.并且PPARδ作为治疗靶点,他的合成激动剂有望开发成为治疗代谢综合症的有效药物.Peroxisome proliferator-activated receptors （PPARs） are a group of well-studied nuclear receptor isoforms. PPARs are intimately connected to cellular metabolism （carbohydrate, lipid and protein） and cell differentiation. PPARs are ligand-activated transcription factors, as well as being a group of nuclear receptor isoforms. Since PPARs were first reported in the 1990s, their biological functions in cellular metabolism, differentiation and disease relative effects have been thoroughly investigated. PPARs have three subtypes, PPARα, PPARδ/β and PPARγ. The biological function and relationship to disease of PPAR5 have become the focus of research, with the discovery of a special selective agonist of PPAR6. PPAR5 is one of the main factors that regulate adipocyte differentiation and energy dissipation. Furthermore, PPAR5 also participates in the development of several diseases. PPAR5 agonists are expected to become effective drugs for treating metabolic syndrome.

关 键 词：过氧化物酶增殖物激活受体 

分 类 号：R341[医药卫生—基础医学]